Home / Pharmaceuticals / Multiple Drug Resistance Bacterial Infection Treatment Market By Vector (Critical, Medium, High), By Drug Class (Cephalosporin, Beta Lactam, Beta Lactamase Inhibitors, Oxazolidinone, Cyclic Lipopeptide, Glycolipopeptides ) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

Multiple Drug Resistance Bacterial Infection Treatment Market By Vector (Critical, Medium, High), By Drug Class (Cephalosporin, Beta Lactam, Beta Lactamase Inhibitors, Oxazolidinone, Cyclic Lipopeptide, Glycolipopeptides ) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

Published: Jul 2017 | Report Code: 58597-07-17

This report on global multiple drug resistance bacterial infection treatment market studies various vectors and drug class. Rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market growth. The limiting factors related to this market are the complex regulatory approvals for the antibiotics which varies according to countries. Promising pipeline of novel antibiotics with more effective mechanism of action to counteract drug resistance by microbes will result into deep market penetration of the multiple drug resistance bacterial infection treatment market.

For the purpose of this study, the vectors studied include critical, high and medium ; drug class studied for the purpose of this research are segmented as cephalosporins, beta lactams, beta lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides and others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global multiple drug resistance bacterial infection treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players.

Multiple Drug Resistance Bacterial Infection Treatment Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market Portraiture
2.1.1. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2016
2.1.2. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2016
2.1.3. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016

Chapter 3. Multiple Drug Resistance Bacterial Infection Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Prevalence Data of Major Target Diseases
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Porter’s Five Forces Analysis
3.7. Attractive Investment Proposition, by Geography
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector
4.3. Critical
4.3.1. Acinetobacter baumanni (Carbapenem-Resistant)
4.3.2. Pseudomonas aeruginosa (Carbapenem-Resistant)
4.3.3. Enterobacteriaceae (Carbapenem-Resistant)
4.4. Medium
4.4.1. Enterococcus faecium (Vancomycin-Resistant)
4.4.2. Helicobacter pylori (Clarithromycin-Resistant)
4.4.3. Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
4.4.4. Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
4.5. High
4.5.1. Streptococcus pneumonia (Penicillin-Non-Susceptible)
4.5.2. Haemophilus influenza (Ampicillin-Resistant)
4.5.3. Shigella spp. (Fluoroquinolone-Resistant)
4.5.4. Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

Chapter 5. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class
5.2. Cephalosporin
5.2.1. Cefixime (3rd Generation)
5.2.2. Ceftriaxone (3rd Generation
5.2.3. Ceftobiprole (5th Generation)
5.3. Beta Lactam
5.3.1. Doripenem
5.3.2. Imipenem
5.3.3. Meropenem
5.3.4. Ceftazidime
5.4. Beta Lactamase Inhibitors
5.4.1. Sulbactam
5.4.2. Tazobactum
5.4.3. Avibactum
5.4.4. Clavam
5.5. Oxazolidinone
5.5.1. Linezolid
5.6. Cyclic Lipopeptide
5.6.1. Daptomycin
5.7. Glycolipopeptides
5.7.1. Dalbavancin
5.7.2. Vancomycin
5.8. Others
5.8.1. Polymixins
5.8.2. Tetracycline and Derivatives
5.8.3. Penicillins
5.8.4. Macrolides
5.8.5. Macrolide-Lincosamide-Streptogramin
5.8.6. Rifamycins
5.8.7. Fluoroquinolones
5.8.8. Nitroimidazole
5.8.9. Bismuth Subcitrate Potassium

Chapter 6. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.2.1. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.2.2. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.3. North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.3.1. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.3.2. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.3. Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. France
6.3.3.4. Rest of Europe
6.4. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.5.1. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Multiple Drug Resistance Bacterial Infection Treatment Market Analysis, 2015 – 2025
6.6.1. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
6.6.2. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.3. MEA Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Vector Portfolio
7.1.4. Key Developments
7.2. Actelion Pharmaceuticals Ltd.
7.3. Albany Molecular Research, Inc.
7.4. Allergan plc.
7.5. AstraZeneca
7.6. Bayer AG
7.7. Biocon
7.8. Daiichi Sankyo Company
7.9. GlaxoSmithKline plc.
7.10. Macrolide Pharmaceuticals, Inc.
7.11. Merck & Co, Inc.
7.12. Pfizer, Inc.
7.13. Sanofi
7.14. Teva Pharmaceuticals Industries Ltd.
7.15. Wockhardt
7.16. Zavante Therapeutics, Inc.
7.17. Other Notable Players

List Of Table :

TABLE 1 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 2 Global Critical Vector Market, 2015 – 2025 (US$ Mn)
TABLE 3 Global High Vector Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Medium Vector Market, 2015 – 2025 (US$ Mn)
TABLE 5 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Cephalosporin Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Beta Lactam Market, 2015 – 2025 (US$ Mn)
TABLE 8 Global Beta Lactamase Inhibitors Market, 2015 – 2025 (US$ Mn)
TABLE 9 Global Oxazolidinone Market, 2015 – 2025 (US$ Mn)
TABLE 10 Global Cyclic Lipopeptide Market, 2015 – 2025 (US$ Mn)
TABLE 11 Global Glycolipopeptides Market, 2015 – 2025 (US$ Mn)
TABLE 12 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 13 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 14 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 15 North America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 17 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 18 Europe Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 19 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 20 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 21 Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 22 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 24 Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 25 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 – 2025 (US$ Mn)
TABLE 26 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 27 Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 28 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 29 Actelion Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 30 Albany Molecular Research, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 31 Allergan plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 32 AstraZeneca: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 33
TABLE 34 Bayer AG: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 35 Biocon: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 36 Daiichi Sankyo Company: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 37 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 38 Macrolide Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 39 Merck & Co, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 40 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 41 Sanofi: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 42 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 43 Wockhardt: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)
TABLE 44 Zavante Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Vector Portfolio; News Coverage)

List Of Figures :

FIG. 1 Multiple Drug Resistance Bacterial Infection Treatment Market: Segmentation
FIG. 2 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Vector, 2016 (Value %)
FIG. 3 Global Multiple Drug Resistance Bacterial Infection Treatment Market Share, by Drug Class, 2016 (Value %)
FIG. 4 Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Acinetobacter baumanni Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Pseudomonas aeruginosa Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Enterobacteriaceae Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Enterococcuc faecium Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Helicobacter pylori Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Staphylococcus aureus Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Neisseria gonorrhea Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Steptococcus pneumonia Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Haemophilus influenza Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Shigella spp. Market, 2015 – 2025 (US$ Mn)
FIG. 17 Global Clostridium difficile Market, 2015 – 2025 (US$ Mn)
FIG. 18 Global Cefixime Market, 2015 – 2025 (US$ Mn)
FIG. 19 Global Ceftriaxone Market, 2015 – 2025 (US$ Mn)
FIG. 20 Global Ceftobiprole Market, 2015 – 2025 (US$ Mn)
FIG. 21 Global Doripenem Market, 2015 – 2025 (US$ Mn)
FIG. 22 Global Imipenem Market, 2015 – 2025 (US$ Mn)
FIG. 23 Global Meropenem Market, 2015 – 2025 (US$ Mn)
FIG. 24 Global Ceftazidime Market, 2015 – 2025 (US$ Mn)
FIG. 25 Global Sulbactam Market, 2015 – 2025 (US$ Mn)
FIG. 26 Global Tazobactam Market 2015 – 2025 (US$ Mn)
FIG. 27 Global Avibactam Market, 2015 – 2025 (US$ Mn)
FIG. 28 Global Clavam Market, 2015 – 2025 (US$ Mn)
FIG. 29 Global Linezolid Market, 2015 – 2025 (US$ Mn)
FIG. 30 Global Daptomycin Market, 2015 – 2025 (US$ Mn)
FIG. 31 Global Dalbavancin Market, 2015 – 2025 (US$ Mn)
FIG. 32 Global Vancomycin Market, 2015 – 2025 (US$ Mn)
FIG. 33 Global Others Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 34 U.S. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 35 Canada Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 36 U.K. Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 37 Germany Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 38 France Multiple Drug Resistance Bacterial Infection Treatment Market, 2015-2025 (US$ Mn)
FIG. 39 Rest of Europe Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 40 Japan Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 41 China Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 42 India Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 43 Rest of Asia Pacific Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 44 Brazil Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 45 Mexico Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 46 Rest of Latin America Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 47 GCC Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 48 Rest of Middle East and Africa Multiple Drug Resistance Bacterial Infection Treatment Market, 2015 – 2025 (US$ Mn)

 

Based on drug class, the multiple drug resistance bacterial infection treatment market is categorized into

  • Cephalosporin
    • Cefixime (3rd Generation)
    • Ceftriaxone (3rd Generation
    • Ceftobiprole (5th Generation)
  • Beta Lactam
    • Doripenem
    • Imipenem
    • Meropenem
    • Ceftazidime
  • Beta Lactamase Inhibitors
    • Sulbactam
    • Tazobactum
    • Avibactum
    • Clavam
  • Oxazolidinone
    • Linezolid
  • Cyclic Lipopeptide
    • Daptomycin
  • Glycolipopetides
    • Dalbavancin
    • Vancomycin
  • Others
    • Polymixins
    • Tetracycline and Derivatives
    • Penicillins
    • Macrolides
    • Macrolide-Lincosamide-Streptogramin
    • Rifamycins
    • Fluoroquinolones
    • Nitroimidazole
    • Bismuth Subcitrate Potassium

Multiple Drug Resistance Bacterial Infection Treatment Market

Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. World Health Organization (WHO) 2015 awareness guidelines suggest that in order to prevent and control antibiotic resistance use only the prescribed antibiotics, never share or use leftover antibiotics and prevent infection by maintaining personal hygiene, consumption of hygienic food and water, practice safe sex and keep vaccination up to date. The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are, rising prevalence of antibiotic resistance and promising pipeline to counteract existing drug resistance. In 2016 the beta Lactam drugs held the largest market due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance, and broad spectrum activity delivered by beta lactam drugs such as Ceftazidime-avibactam and Doripenem. Oxazolidinone and Glycolipopeptides will be the fastest growing segments throughout the forecast period 2017-2025, majorly due to factors such as increasing patient pool suffering with Enterococcus faecium and Staphylococcus aureus methicillin and vancomycin resistance, improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin. Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co, Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., and other notable players etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the novel antibiotics to counteract drug resistance and better pharmacokinetic activities for better patient compliance and available at low cost.

Based on vector, the global multiple drug resistance bacterial infection treatment market is categorized into

  • Critical
    • Acinetobacter baumanni (Carbapenem Resistant)
    • Pseudomonas aeruginosa (Carbapenem Resistant)
    • Enterobacteriaceae (Carbapenem Resistant)
  • High
    • Enterococcus faecium (Vancomycin-Resistant)
    • Helicobacter pylori (Clarithromycin-Resistant)
    • Staphylococcus aureus (Methicillin-Resistant, Vancomycin Intermediate And Resistant)
    • Neisseria gonorrhea (Cephalosporin-Resistant, Fluoroquinolone-Resistant)
  • Medium
    • Streptococcus pneumonia (Penicillin-Non-Susceptible)
    • Haemophilus influenza (Ampicillin-Resistant)
    • Shigella spp. (Fluoroquinolone-Resistant)
    • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

Multiple Drug Resistance Bacterial Infection Treatment Market

As per the Assistant Secretary for Preparedness and Response (ASPR) 2015 report of Department of Health and Human Services over the past 15 years there has been 15 entries and 36 corporate exits involved in the antimicrobial treatment. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market chiefly due to factors such as rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and lack of novel drug launch in the Beta lactam antibiotics will serve great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. High segment will be the fastest growing market throughout the forecast period 2017-2025, due to the extensive growth in the Helicobacter pylori (clarithromycin-resistant), and Staphylococcus aureus, (methicillin-resistant, vancomycin-intermediate and resistant) infections and recent launch of novel drug formulation Pylera used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, Daptomycin and Dalvabancin has effective mechanism of action in comparison to vancomycin in the antibiotic resistance treatment

For the purpose of this study, the global multiple drug resistance bacterial infection treatment market is categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Multiple Drug Resistance Bacterial Infection Treatment Market

North America was observed as the largest market for multiple drug resistance bacterial infection treatment market in the base year 2016. According to Department of Health and Human Services of CDC report 2015 approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly due to rising prevalence of multiple drug resistance cases, evolved health infrastructure and affordable reimbursement scenario. According to the European Centre for Disease Prevention and Control approximately 25,000 deaths were associated with multidrug resistant bacterial infection; the growth is chiefly attributed due to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment, and supportive regulatory approval for launch of new antibiotics for the treatment of multiple drug resistance. Asia Pacific will be the fastest growing regional segment throughout the forecast period 2017-2025, the growth is attributed by factors like rising prevalence of geriatric population suffering with multiple drug resistance bacterial infection and increasing disposable income in these regions. Factors such as developing health infrastructure, increasing awareness regarding the judicious use of prescribed antibiotics especially in the remote areas are going to fuel the rapid growth of multiple drug resistance bacterial infection treatment market in Latin America and Middle East and Africa region in the near future.   

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients